Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Dec 17;11:6410. doi: 10.1038/s41467-020-19917-0

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2020

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 4 — a Gene ontology analysis of differentially regulated processes in primary (blue) versus transplant (red) sarcomas after isotype treatment. b Spearman correlation analysis of bulk tumor RNA from primary tumors (n = 8) and untreated human UPS (TCGA, n = 87). c Spearman correlation of bulk tumor RNA from transplant tumors (n = 4) and untreated human UPS (TCGA, n = 87). d Cellular composition of TCGA sarcomas (DDLPS, dedifferentiated liposarcoma; LMS, leiomyosarcoma; UPS, undifferentiated pleomorphic sarcoma) (n = 218) separated by previously defined sarcoma immune class (SIC, left) and murine primary sarcomas (right). Sample sizes: SIC A (n = 57), SIC B (n = 52), SIC C (n = 36), SIC D (n = 34), SIC E (n = 39), primary (n = 8), and transplant (n = 4). e Immune cell content of TCGA sarcomas by sarcoma immune class (SIC) and murine sarcomas. Sample sizes: SIC A (n = 6), SIC B (n = 21), SIC C (n = 7), SIC D (n = 9), SIC E (n = 17), primary (n = 8), and transplant (n = 4). Significance determined by two-sided Wilcoxon test. f Immune cell composition of TCGA sarcomas by sarcoma immune class (SIC) and murine sarcomas. In b–f, cell proportions enumerated by CIBERSORTx. Source data are provided as a Source data file.